| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3268516 | HPB | 2016 | 8 Pages |
Abstract
These results demonstrate a survival benefit with the addition of LRTx to sorafenib for patients with advanced HCC. These findings should prompt a prospective clinical trial to further assess the role of LRTx in patients with advanced HCC.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Umut Sarpel, John H. Spivack, Yaniv Berger, Marina Heskel, Samantha N. Aycart, Robert Sweeney, Martin P. Edwards, Daniel M. Labow, Edward Kim,